Prediction of skin sensitizers using alternative methods to animal experimentation

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 1, 2014, Pages 110-117

  Johansson, Henrik ^a   Lindstedt, Malin ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR7; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; GAMMA INTERFERON; HAPTEN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; KERATIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; REACTIVE OXYGEN METABOLITE; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; DANGEROUS GOODS;

ADAPTIVE IMMUNITY; ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL TESTING ALTERNATIVE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELL STRESS; CONTACT DERMATITIS; COVALENT BOND; DENDRITIC CELL; DIRECT PEPTIDE REACTIVITY ASSAY; GENOMIC ALLERGEN RAPID DETECTION ASSAY; GUINEA PIG MAXIMIZATION TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOST CELL; HUMAN CELL LINE ACTIVATION TEST; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL MEMORY; KERATINOCYTE; KERATINOSENS; LANGERHANS CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC ACTIVATION; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK ASSESSMENT; SKIN ALLERGY; SKIN SENSITIZATION; UPREGULATION; VITOSENS; XENOBIOTIC METABOLISM; ANIMAL; DANGEROUS GOODS; DRUG EFFECTS; HUMAN; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; PROCEDURES; SKIN; TOXICITY TESTING;

ANIMALIA;

ANIMAL EXPERIMENTATION; ANIMAL TESTING ALTERNATIVES; ANIMALS; HAZARDOUS SUBSTANCES; HUMANS; IMMUNITY, INNATE; RISK ASSESSMENT; SKIN; TOXICITY TESTS;

EID: 84902120802     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12199     Document Type: Article

References (47)

1. Kimber I, Basketter DA, Gerberick GF, Dearman RJ. Allergic contact dermatitis. Int Immunopharmacol 2002;2:201-11.
2. Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. Int Arch Occup Environ Health 1999;72:496-506.
3. Basketter DA, Evans P, Fielder RJ, Gerberick GF, Dearman RJ, Kimber I. Local lymph node assay - validation, conduct and use in practice. Food Chem Toxicol 2002;40:593-8.
4. Magnusson B, Kligman AM. The identification of contact allergens by animal assay. The guinea pig maximization test. J Invest Dermatol 1969;52:268-76.
5. 76/768/EEC CD. http://ec.europa.eu/consumers/sectors/cosmetics/documents/directive/index_en.htm/February2014.
6. Gerberick GF, Ryan CA, Kern PS, Schlatter H, Dearman RJ, Kimber I et al. Compilation of historical local lymph node data for evaluation of skin sensitization alternative methods. Dermatitis 2005;16:157-202.
7. Kern PS, Gerberick GF, Ryan CA, Kimber I, Aptula A, Basketter DA. Local lymph node data for the evaluation of skin sensitization alternatives: a second compilation. Dermatitis 2010;21:8-32.
8. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds: Iii. Anaphylaxis induced by Arsphenamine. J Exp Med 1936;64:717-21.
9. Simonsson C, Andersson SI, Stenfeldt AL, Bergstrom J, Bauer B, Jonsson CA et al. Caged fluorescent haptens reveal the generation of cryptic epitopes in allergic contact dermatitis. J Invest Dermatol 2011;131:1486-93.
10. Chipinda I, Hettick JM, Siegel PD. Haptenation: chemical reactivity and protein binding. J Allergy (Cairo) 2011;2011:839682.
11. Kimber I, Cumberbatch M, Dearman RJ. Langerhans cell migration: not necessarily always at the center of the skin sensitization universe. J Invest Dermatol 2009;129:1852-3.
12. Cumberbatch M, Bhushan M, Dearman RJ, Kimber I, Griffiths CE. IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol 2003;132:352-9.
13. Cumberbatch M, Griffiths CE, Tucker SC, Dearman RJ, Kimber I. Tumour necrosis factor-alpha induces Langerhans cell migration in humans. Br J Dermatol 1999;141:192-200.
14. Griffiths CE, Dearman RJ, Cumberbatch M, Kimber I. Cytokines and Langerhans cell mobilisation in mouse and man. Cytokine 2005;32:67-70.
15. Xu H, DiIulio NA, Fairchild RL. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells. J Exp Med 1996;183:1001-12.
16. Martin SF. T lymphocyte-mediated immune responses to chemical haptens and metal ions: implications for allergic and autoimmune disease. Int Arch Allergy Immunol 2004;134:186-98.
17. Cavani A, Albanesi C, Traidl C, Sebastiani S, Girolomoni G. Effector and regulatory T cells in allergic contact dermatitis. Trends Immunol 2001;22:118-20.
18. Tsuji RF, Kawikova I, Ramabhadran R, Akahira-Azuma M, Taub D, Hugli TE et al. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol 2000;165:1588-98.
19. Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, Sozzani S et al. A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J Leukoc Biol 2001;70:617-23.
20. Matzinger P. An innate sense of danger. Semin Immunol 1998;10:399-415.
21. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291-5.
22. Martin SF, Dudda JC, Bachtanian E, Lembo A, Liller S, Durr C et al. Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med 2008;205:2151-62.
23. Schmidt M, Raghavan B, Muller V, Vogl T, Fejer G, Tchaptchet S et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010;11:814-9.
24. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006;24:317-27.
25. Watanabe H, Gaide O, Petrilli V, Martinon F, Contassot E, Roques S et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007;127:1956-63.
26. Esser PR, Wolfle U, Durr C, von Loewenich FD, Schempp CM, Freudenberg MA et al. Contact sensitizers induce skin inflammation via ROS production and hyaluronic acid degradation. PLoS ONE 2012;7:e41340.
27. Kalmes M, Hennen J, Clemens J, Blomeke B. Impact of aryl hydrocarbon receptor (AhR) knockdown on cell cycle progression in human HaCaT keratinocytes. Biol Chem 2011;392:643-51.
28. Skazik C, Heise R, Ott H, Czaja K, Marquardt Y, Merk HF et al. Active transport of contact allergens in human monocyte-derived dendritic cells is mediated by multidrug resistance related proteins. Arch Biochem Biophys 2011;508:212-6.
29. Buehler EV. Delayed contact hypersensitivity in the Guinea pig. Arch Dermatol 1965;91:171-7.
30. HaSPSoTaA OE. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. 2012;168:1-59. http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282012%2910/part1&doclanguage=en/February2014.
31. Gerberick GF, Vassallo JD, Bailey RE, Chaney JG, Morrall SW, Lepoittevin JP. Development of a peptide reactivity assay for screening contact allergens. Toxicol Sci 2004;81:332-43.
32. Johansson H, Lindstedt M, Albrekt AS, Borrebaeck CA. A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 2011;12:399.
33. Lindstedt M, Borrebaeck C. Pattern rules: biomarker signatures for sensitization as an alternative to animal testing. Biomark Med 2011;5:809-11.
34. Natsch A, Ryan CA, Foertsch L, Emter R, Jaworska J, Gerberick F et al. A dataset on 145 chemicals tested in alternative assays for skin sensitization undergoing prevalidation. J Appl Toxicol 2013; doi: 10.1002/jat.2869.
35. Ashikaga T, Yoshida Y, Hirota M, Yoneyama K, Itagaki H, Sakaguchi H et al. Development of an in vitro skin sensitization test using human cell lines: the human Cell Line Activation Test (h-CLAT). I. Optimization of the h-CLAT protocol. Toxicol In Vitro 2006;20:767-73.
36. Nukada Y, Ashikaga T, Sakaguchi H, Sono S, Mugita N, Hirota M et al. Predictive performance for human skin sensitizing potential of the human cell line activation test (h-CLAT). Contact Dermat 2011;65:343-53.
37. Sakaguchi H, Ryan C, Ovigne JM, Schroeder KR, Ashikaga T. Predicting skin sensitization potential and inter-laboratory reproducibility of a human Cell Line Activation Test (h-CLAT) in the European Cosmetics Association (COLIPA) ring trials. Toxicol In Vitro 2010;24:1810-20.
38. Hooyberghs J, Schoeters E, Lambrechts N, Nelissen I, Witters H, Schoeters G et al. A cell-based in vitro alternative to identify skin sensitizers by gene expression. Toxicol Appl Pharmacol 2008;231:103-11.
39. Lambrechts N, Nelissen I, Van Tendeloo V, Witters H, Van Den Heuvel R, Hooyberghs J et al. Functionality and specificity of gene markers for skin sensitization in dendritic cells. Toxicol Lett 2011;203:106-10.
40. Johansson H, Albrekt AS, Borrebaeck CA, Lindstedt M. The GARD assay for assessment of chemical skin sensitizers. Toxicol In Vitro 2013;27:1163-9.
41. Patlewicz G, Aptula AO, Uriarte E, Roberts DW, Kern PS, Gerberick GF et al. An evaluation of selected global (Q)SARs/expert systems for the prediction of skin sensitisation potential. SAR QSAR Environ Res 2007;18:515-41.
42. Teubner W, Mehling A, Schuster PX, Guth K, Worth A, Burton J et al. Computer models versus reality: how well do in silico models currently predict the sensitization potential of a substance. Regul Toxicol Pharmacol 2013;67:468-85.
43. Kinsner-Ovaskainen A, Akkan Z, Casati S, Coecke S, Corvi R, Dal Negro G et al. Overcoming barriers to validation of non-animal partial replacement methods/integrated testing strategies: the report of an EPAA-ECVAM workshop. Altern Lab Anim 2009;37:437-44.
44. Kinsner-Ovaskainen A, Maxwell G, Kreysa J, Barroso J, Adriaens E, Alepee N et al. Report of the EPAA-ECVAM workshop on the validation of Integrated Testing Strategies (ITS). Altern Lab Anim 2012;40:175-81.
45. Hoffmann S, Hartung T. Toward an evidence-based toxicology. Hum Exp Toxicol 2006;25:497-513.
46. Jaworska J, Dancik Y, Kern P, Gerberick F, Natsch A. Bayesian integrated testing strategy to assess skin sensitization potency: from theory to practice. J Appl Toxicol 2013; doi: 10.1002/jat.2869.
47. Bauch C, Kolle SN, Fabian E, Pachel C, Ramirez T, Wiench B et al. Intralaboratory validation of four in vitro assays for the prediction of the skin sensitizing potential of chemicals. Toxicol In Vitro 2011;25:1162-8.